Marshall Wace LLP Decreases Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Marshall Wace LLP cut its holdings in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 82.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,172 shares of the company’s stock after selling 51,531 shares during the period. Marshall Wace LLP’s holdings in Checkpoint Therapeutics were worth $36,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of CKPT. Raymond James Financial Inc. purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at about $67,000. Geode Capital Management LLC boosted its holdings in Checkpoint Therapeutics by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock worth $1,425,000 after purchasing an additional 17,460 shares during the last quarter. Virtu Financial LLC grew its position in Checkpoint Therapeutics by 180.5% in the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock worth $122,000 after purchasing an additional 24,552 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in Checkpoint Therapeutics during the 4th quarter valued at $64,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Checkpoint Therapeutics during the 4th quarter valued at $32,000. 22.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on CKPT. Lake Street Capital reiterated a “hold” rating and set a $4.10 price objective (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. D. Boral Capital reiterated a “buy” rating and issued a $4.80 price objective on shares of Checkpoint Therapeutics in a research note on Monday, March 31st. Finally, HC Wainwright restated a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Insider Activity

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 74,110 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the sale, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. This trade represents a 4.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO James F. Oliviero III sold 9,233 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at $12,908,043.50. This trade represents a 0.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 121,086 shares of company stock worth $446,879 in the last three months. Company insiders own 2.10% of the company’s stock.

Checkpoint Therapeutics Stock Performance

NASDAQ:CKPT opened at $4.15 on Wednesday. The stock has a 50-day simple moving average of $3.86 and a two-hundred day simple moving average of $3.59. The firm has a market capitalization of $347.20 million, a PE ratio of -2.25 and a beta of 1.18. Checkpoint Therapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The company had revenue of $0.04 million for the quarter. Equities analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.